The role of lipoprotein-associated phospholipase A2 in the metabolic syndrome and diabetes

Hiroshi Noto, Pranav Chitkara, Philip Raskin

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Objectives: Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a novel inflammation marker. We investigated its association with other coronary risk factors and evaluated its role as a comprehensive marker of the metabolic syndrome in individuals with type 2 diabetes. Methods: Our cross-sectional study evaluated 92 insulin-treated subjects with type 2 diabetes. Biochemical measurements of Lp-PLA2, glycemic control, lipid profiles, and C-reactive protein were carried out. Seventy-seven subjects were diagnosed as having the metabolic syndrome, which was defined according to the American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Results: Lp-PLA2 was significantly correlated with waist-hip ratio (r=.25), triglycerides (r=.50), high-density lipoprotein cholesterol (r=-.31), and low-density lipoprotein cholesterol (LDL-C; r=.27; all P<.02). In a multiple-regression model, triglycerides and LDL-C levels were the significant predictors of Lp-PLA2. Lp-PLA2 was significantly higher in subjects with the metabolic syndrome than in those without it (268±23.4 vs. 127±15.8 ng/ml, P<.001). There was a linear increase in Lp-PLA2 with an increment of the number of the metabolic syndrome criteria (Ptrend=.041). Another multiple-regression model showed that the hypertriglyceridemia component was the only predictor of Lp-PLA2. Conclusions: Our findings suggest that Lp-PLA2 assay potentially facilitates a more comprehensive assessment of the metabolic syndrome in patients with type 2 diabetes on insulin.

Original languageEnglish (US)
Pages (from-to)343-348
Number of pages6
JournalJournal of Diabetes and its Complications
Volume20
Issue number6
DOIs
StatePublished - Nov 2006

Fingerprint

1-Alkyl-2-acetylglycerophosphocholine Esterase
Type 2 Diabetes Mellitus
Insulin
National Heart, Lung, and Blood Institute (U.S.)
Waist-Hip Ratio
Hypertriglyceridemia
C-Reactive Protein
LDL Cholesterol
HDL Cholesterol
Triglycerides
Cross-Sectional Studies
Inflammation
Lipids

Keywords

  • Inflammation
  • Insulin resistance
  • Lipoprotein-associated phospholipase A (Lp-PLA)
  • Metabolic syndrome
  • Platelet-activating factor-acetylhydrolase (PAF-AH)

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

The role of lipoprotein-associated phospholipase A2 in the metabolic syndrome and diabetes. / Noto, Hiroshi; Chitkara, Pranav; Raskin, Philip.

In: Journal of Diabetes and its Complications, Vol. 20, No. 6, 11.2006, p. 343-348.

Research output: Contribution to journalArticle

@article{3746627f77314709a36436060d4618d7,
title = "The role of lipoprotein-associated phospholipase A2 in the metabolic syndrome and diabetes",
abstract = "Objectives: Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a novel inflammation marker. We investigated its association with other coronary risk factors and evaluated its role as a comprehensive marker of the metabolic syndrome in individuals with type 2 diabetes. Methods: Our cross-sectional study evaluated 92 insulin-treated subjects with type 2 diabetes. Biochemical measurements of Lp-PLA2, glycemic control, lipid profiles, and C-reactive protein were carried out. Seventy-seven subjects were diagnosed as having the metabolic syndrome, which was defined according to the American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Results: Lp-PLA2 was significantly correlated with waist-hip ratio (r=.25), triglycerides (r=.50), high-density lipoprotein cholesterol (r=-.31), and low-density lipoprotein cholesterol (LDL-C; r=.27; all P<.02). In a multiple-regression model, triglycerides and LDL-C levels were the significant predictors of Lp-PLA2. Lp-PLA2 was significantly higher in subjects with the metabolic syndrome than in those without it (268±23.4 vs. 127±15.8 ng/ml, P<.001). There was a linear increase in Lp-PLA2 with an increment of the number of the metabolic syndrome criteria (Ptrend=.041). Another multiple-regression model showed that the hypertriglyceridemia component was the only predictor of Lp-PLA2. Conclusions: Our findings suggest that Lp-PLA2 assay potentially facilitates a more comprehensive assessment of the metabolic syndrome in patients with type 2 diabetes on insulin.",
keywords = "Inflammation, Insulin resistance, Lipoprotein-associated phospholipase A (Lp-PLA), Metabolic syndrome, Platelet-activating factor-acetylhydrolase (PAF-AH)",
author = "Hiroshi Noto and Pranav Chitkara and Philip Raskin",
year = "2006",
month = "11",
doi = "10.1016/j.jdiacomp.2006.07.004",
language = "English (US)",
volume = "20",
pages = "343--348",
journal = "Journal of Diabetes and its Complications",
issn = "1056-8727",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - The role of lipoprotein-associated phospholipase A2 in the metabolic syndrome and diabetes

AU - Noto, Hiroshi

AU - Chitkara, Pranav

AU - Raskin, Philip

PY - 2006/11

Y1 - 2006/11

N2 - Objectives: Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a novel inflammation marker. We investigated its association with other coronary risk factors and evaluated its role as a comprehensive marker of the metabolic syndrome in individuals with type 2 diabetes. Methods: Our cross-sectional study evaluated 92 insulin-treated subjects with type 2 diabetes. Biochemical measurements of Lp-PLA2, glycemic control, lipid profiles, and C-reactive protein were carried out. Seventy-seven subjects were diagnosed as having the metabolic syndrome, which was defined according to the American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Results: Lp-PLA2 was significantly correlated with waist-hip ratio (r=.25), triglycerides (r=.50), high-density lipoprotein cholesterol (r=-.31), and low-density lipoprotein cholesterol (LDL-C; r=.27; all P<.02). In a multiple-regression model, triglycerides and LDL-C levels were the significant predictors of Lp-PLA2. Lp-PLA2 was significantly higher in subjects with the metabolic syndrome than in those without it (268±23.4 vs. 127±15.8 ng/ml, P<.001). There was a linear increase in Lp-PLA2 with an increment of the number of the metabolic syndrome criteria (Ptrend=.041). Another multiple-regression model showed that the hypertriglyceridemia component was the only predictor of Lp-PLA2. Conclusions: Our findings suggest that Lp-PLA2 assay potentially facilitates a more comprehensive assessment of the metabolic syndrome in patients with type 2 diabetes on insulin.

AB - Objectives: Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a novel inflammation marker. We investigated its association with other coronary risk factors and evaluated its role as a comprehensive marker of the metabolic syndrome in individuals with type 2 diabetes. Methods: Our cross-sectional study evaluated 92 insulin-treated subjects with type 2 diabetes. Biochemical measurements of Lp-PLA2, glycemic control, lipid profiles, and C-reactive protein were carried out. Seventy-seven subjects were diagnosed as having the metabolic syndrome, which was defined according to the American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Results: Lp-PLA2 was significantly correlated with waist-hip ratio (r=.25), triglycerides (r=.50), high-density lipoprotein cholesterol (r=-.31), and low-density lipoprotein cholesterol (LDL-C; r=.27; all P<.02). In a multiple-regression model, triglycerides and LDL-C levels were the significant predictors of Lp-PLA2. Lp-PLA2 was significantly higher in subjects with the metabolic syndrome than in those without it (268±23.4 vs. 127±15.8 ng/ml, P<.001). There was a linear increase in Lp-PLA2 with an increment of the number of the metabolic syndrome criteria (Ptrend=.041). Another multiple-regression model showed that the hypertriglyceridemia component was the only predictor of Lp-PLA2. Conclusions: Our findings suggest that Lp-PLA2 assay potentially facilitates a more comprehensive assessment of the metabolic syndrome in patients with type 2 diabetes on insulin.

KW - Inflammation

KW - Insulin resistance

KW - Lipoprotein-associated phospholipase A (Lp-PLA)

KW - Metabolic syndrome

KW - Platelet-activating factor-acetylhydrolase (PAF-AH)

UR - http://www.scopus.com/inward/record.url?scp=33750326112&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750326112&partnerID=8YFLogxK

U2 - 10.1016/j.jdiacomp.2006.07.004

DO - 10.1016/j.jdiacomp.2006.07.004

M3 - Article

C2 - 17070436

AN - SCOPUS:33750326112

VL - 20

SP - 343

EP - 348

JO - Journal of Diabetes and its Complications

JF - Journal of Diabetes and its Complications

SN - 1056-8727

IS - 6

ER -